141 related articles for article (PubMed ID: 9703255)
1. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine).
Ishikawa T; Fukase Y; Yamamoto T; Sekiguchi F; Ishitsuka H
Biol Pharm Bull; 1998 Jul; 21(7):713-7. PubMed ID: 9703255
[TBL] [Abstract][Full Text] [Related]
2. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.
Ishikawa T; Utoh M; Sawada N; Nishida M; Fukase Y; Sekiguchi F; Ishitsuka H
Biochem Pharmacol; 1998 Apr; 55(7):1091-7. PubMed ID: 9605432
[TBL] [Abstract][Full Text] [Related]
3. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.
Ishikawa T; Sekiguchi F; Fukase Y; Sawada N; Ishitsuka H
Cancer Res; 1998 Feb; 58(4):685-90. PubMed ID: 9485021
[TBL] [Abstract][Full Text] [Related]
4. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Endo M; Shinbori N; Fukase Y; Sawada N; Ishikawa T; Ishitsuka H; Tanaka Y
Int J Cancer; 1999 Sep; 83(1):127-34. PubMed ID: 10449619
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies on the antitumor and immunosuppressive effects of the new fluorouracil derivative N4-trimethoxybenzoyl-5'-deoxy-5-fluorocytidine and its parent drug 5'-deoxy-5-fluorouridine.
Miwa M; Ishikawa T; Eda H; Ryu M; Fujimoto K; Ninomiya Y; Umeda I; Yokose K; Ishitsuka H
Chem Pharm Bull (Tokyo); 1990 Apr; 38(4):998-1003. PubMed ID: 2143107
[TBL] [Abstract][Full Text] [Related]
6. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Fujimoto-Ouchi K; Tanaka Y; Tominaga T
Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
[TBL] [Abstract][Full Text] [Related]
7. [Discovery and development of novel anticancer drug capecitabine].
Ishitsuka H; Shimma N; Horii I
Yakugaku Zasshi; 1999 Dec; 119(12):881-97. PubMed ID: 10630095
[TBL] [Abstract][Full Text] [Related]
8. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Miwa M; Ura M; Nishida M; Sawada N; Ishikawa T; Mori K; Shimma N; Umeda I; Ishitsuka H
Eur J Cancer; 1998 Jul; 34(8):1274-81. PubMed ID: 9849491
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine: preclinical pharmacology studies.
Ishitsuka H
Invest New Drugs; 2000 Nov; 18(4):343-54. PubMed ID: 11081570
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models.
Fujimoto-Ouchi K; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2002 Mar; 49(3):211-6. PubMed ID: 11935213
[TBL] [Abstract][Full Text] [Related]
11. Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Ninomiya I; Terada I; Yoshizumi T; Takino T; Nagai N; Morita A; Fushida S; Nishimura G; Fujimura T; Ohta T; Miwa K
Int J Cancer; 2004 Oct; 112(1):135-42. PubMed ID: 15305385
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.
Armstrong RD; Diasio RB
Cancer Res; 1980 Sep; 40(9):3333-8. PubMed ID: 6253060
[TBL] [Abstract][Full Text] [Related]
13. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
[TBL] [Abstract][Full Text] [Related]
14. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.
Sawada N; Ishikawa T; Sekiguchi F; Tanaka Y; Ishitsuka H
Clin Cancer Res; 1999 Oct; 5(10):2948-53. PubMed ID: 10537364
[TBL] [Abstract][Full Text] [Related]
15. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.
Sawada N; Ishikawa T; Fukase Y; Nishida M; Yoshikubo T; Ishitsuka H
Clin Cancer Res; 1998 Apr; 4(4):1013-9. PubMed ID: 9563897
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.
Cao D; Ziemba A; McCabe J; Yan R; Wan L; Kim B; Gach M; Flynn S; Pizzorno G
Mol Cancer Ther; 2011 Dec; 10(12):2330-9. PubMed ID: 21954436
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Morita T; Matsuzaki A; Tokue A
Int J Cancer; 2001 May; 92(3):451-6. PubMed ID: 11291085
[TBL] [Abstract][Full Text] [Related]
18. Relationship between AUC of 5'-DFUR and toxicity of capecitabine, fluoropyrimidine carbamate analogs, and 5'-DFUR in monkeys, mice, and rats.
Shindoh H; Kawashima A; Shishido N; Nakano K; Kobayashi K; Horii I
J Toxicol Sci; 2006 Aug; 31(3):265-85. PubMed ID: 16960436
[TBL] [Abstract][Full Text] [Related]
19. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine.
Shimma N; Umeda I; Arasaki M; Murasaki C; Masubuchi K; Kohchi Y; Miwa M; Ura M; Sawada N; Tahara H; Kuruma I; Horii I; Ishitsuka H
Bioorg Med Chem; 2000 Jul; 8(7):1697-706. PubMed ID: 10976516
[TBL] [Abstract][Full Text] [Related]
20. Role of administration route in the therapeutic efficacy of doxifluridine.
Trave F; Canobbio L; Au JL; Rustum YM
J Natl Cancer Inst; 1987 Mar; 78(3):527-32. PubMed ID: 2950266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
